The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria

J Allergy Clin Immunol. 2018 Mar;141(3):1138-1139.e7. doi: 10.1016/j.jaci.2017.10.018. Epub 2017 Nov 10.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Middle Aged
  • Omalizumab / administration & dosage*
  • Omalizumab / adverse effects
  • Time Factors
  • Urticaria / drug therapy*
  • Urticaria / immunology
  • Urticaria / pathology

Substances

  • Omalizumab